Please assess the completion status of the following clinical trial:

Trial Title: INNO-105 in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have a histologically or cytologically confirmed diagnosis of a solid malignancy (patients may have either measurable or nonmeasurable disease).~2. Be ≥18 years old.~3. Not eligible for effective therapy likely to provide clinical benefit.~4. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.~5. Acceptable pretreatment clinical laboratory results.~6. Life expectancy of greater than 12 weeks.~Exclusion Criteria:~1. Have received previous treatment with INNO-105.~2. Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.~3. Are pregnant or lactating.~4. Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.~5. Have received any chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational, within 2 weeks of treatment in this study.~6. Have not recovered from acute toxicity of all previous therapy prior to enrollment.~7. Have symptomatic or untreated central nervous system (CNS) metastases.~8. Have a susceptibility to hypotension, bradycardia, and/or hypopnea, such as patients with known coronary heart disease, arrhythmias, cerebral vascular disease, and chronic obstructive airways disease (CO2-retaining).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).